Cargando…
Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism
Single nucleotide polymorphisms (SNPs) reportedly influence the effect of nivolumab in metastatic renal cell carcinoma (mRCC). This study aimed to evaluate the relationship between the clinical outcomes of patients with mRCC and SNPs in programmed cell death protein 1 (PD-1) protein-coding gene (PDC...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324515/ https://www.ncbi.nlm.nih.gov/pubmed/35885987 http://dx.doi.org/10.3390/genes13071204 |
_version_ | 1784756826203488256 |
---|---|
author | Kobayashi, Mizuki Numakura, Kazuyuki Hatakeyama, Shingo Muto, Yumina Sekine, Yuya Sasagawa, Hajime Kashima, Soki Yamamoto, Ryohei Koizumi, Atsushi Nara, Taketoshi Saito, Mitsuru Narita, Shintaro Ohyama, Chikara Habuchi, Tomonori |
author_facet | Kobayashi, Mizuki Numakura, Kazuyuki Hatakeyama, Shingo Muto, Yumina Sekine, Yuya Sasagawa, Hajime Kashima, Soki Yamamoto, Ryohei Koizumi, Atsushi Nara, Taketoshi Saito, Mitsuru Narita, Shintaro Ohyama, Chikara Habuchi, Tomonori |
author_sort | Kobayashi, Mizuki |
collection | PubMed |
description | Single nucleotide polymorphisms (SNPs) reportedly influence the effect of nivolumab in metastatic renal cell carcinoma (mRCC). This study aimed to evaluate the relationship between the clinical outcomes of patients with mRCC and SNPs in programmed cell death protein 1 (PD-1) protein-coding gene (PDCD1) and explore any potential correlation with patient prognosis and incidence of immune-related adverse events (irAEs). In total, 106 patients with mRCC, who were treated with nivolumab alone (n = 59) or nivolumab and ipilimumab (n = 47), were enrolled in the study. Three SNPs in the PDCD1 gene, namely PD-1.3, PD-1.5, and PD-1.6, were assessed. Patients harboring the PD-1.6 G allele experienced more severe (odds ratio, 3.390; 95% confidence interval 1.517–7.756; p = 0.003) and multiple (OR, 2.778; 95% CI, 1.020–6.993 p = 0.031) irAEs than those harboring the AA genotype. Thus, the existence of the PDCD1 PD-1.6 polymorphism (G allele) was associated with the occurrence of severe and multiple irAEs in patients with mRCC. Further evaluation of PDCD1 polymorphisms might help identify patients experiencing irAE by nivolumab treatment. |
format | Online Article Text |
id | pubmed-9324515 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93245152022-07-27 Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism Kobayashi, Mizuki Numakura, Kazuyuki Hatakeyama, Shingo Muto, Yumina Sekine, Yuya Sasagawa, Hajime Kashima, Soki Yamamoto, Ryohei Koizumi, Atsushi Nara, Taketoshi Saito, Mitsuru Narita, Shintaro Ohyama, Chikara Habuchi, Tomonori Genes (Basel) Article Single nucleotide polymorphisms (SNPs) reportedly influence the effect of nivolumab in metastatic renal cell carcinoma (mRCC). This study aimed to evaluate the relationship between the clinical outcomes of patients with mRCC and SNPs in programmed cell death protein 1 (PD-1) protein-coding gene (PDCD1) and explore any potential correlation with patient prognosis and incidence of immune-related adverse events (irAEs). In total, 106 patients with mRCC, who were treated with nivolumab alone (n = 59) or nivolumab and ipilimumab (n = 47), were enrolled in the study. Three SNPs in the PDCD1 gene, namely PD-1.3, PD-1.5, and PD-1.6, were assessed. Patients harboring the PD-1.6 G allele experienced more severe (odds ratio, 3.390; 95% confidence interval 1.517–7.756; p = 0.003) and multiple (OR, 2.778; 95% CI, 1.020–6.993 p = 0.031) irAEs than those harboring the AA genotype. Thus, the existence of the PDCD1 PD-1.6 polymorphism (G allele) was associated with the occurrence of severe and multiple irAEs in patients with mRCC. Further evaluation of PDCD1 polymorphisms might help identify patients experiencing irAE by nivolumab treatment. MDPI 2022-07-05 /pmc/articles/PMC9324515/ /pubmed/35885987 http://dx.doi.org/10.3390/genes13071204 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kobayashi, Mizuki Numakura, Kazuyuki Hatakeyama, Shingo Muto, Yumina Sekine, Yuya Sasagawa, Hajime Kashima, Soki Yamamoto, Ryohei Koizumi, Atsushi Nara, Taketoshi Saito, Mitsuru Narita, Shintaro Ohyama, Chikara Habuchi, Tomonori Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism |
title | Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism |
title_full | Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism |
title_fullStr | Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism |
title_full_unstemmed | Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism |
title_short | Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism |
title_sort | severe immune-related adverse events in patients treated with nivolumab for metastatic renal cell carcinoma are associated with pdcd1 polymorphism |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324515/ https://www.ncbi.nlm.nih.gov/pubmed/35885987 http://dx.doi.org/10.3390/genes13071204 |
work_keys_str_mv | AT kobayashimizuki severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism AT numakurakazuyuki severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism AT hatakeyamashingo severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism AT mutoyumina severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism AT sekineyuya severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism AT sasagawahajime severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism AT kashimasoki severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism AT yamamotoryohei severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism AT koizumiatsushi severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism AT narataketoshi severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism AT saitomitsuru severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism AT naritashintaro severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism AT ohyamachikara severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism AT habuchitomonori severeimmunerelatedadverseeventsinpatientstreatedwithnivolumabformetastaticrenalcellcarcinomaareassociatedwithpdcd1polymorphism |